Cannara Biotech Inc. (TSX:LOVE)
Canada · Delayed Price · Currency is CAD 1.840
-0.050 (-2.65%)
Jul 21, 2026, 11:41 AM EST
Cannara Biotech Cash Flow Statement
Financials in millions CAD. Fiscal year is September - August.
Millions CAD. Fiscal year is Sep - Aug.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | Aug '25 Aug 31, 2025 | Aug '24 Aug 31, 2024 | Aug '23 Aug 31, 2023 | Aug '22 Aug 31, 2022 | Aug '21 Aug 31, 2021 |
Net Income | 10.86 | 13.08 | 6.44 | 6.95 | 2.31 | -1.53 |
Depreciation & Amortization | 6.75 | 6.68 | 6.35 | 4.94 | 3.92 | 3.03 |
Stock-Based Compensation | 3.92 | 1.19 | 1.98 | 1.75 | 0.35 | 0.33 |
Other Adjustments | 7.83 | 5.36 | -1.59 | -2.09 | -1.17 | -0.1 |
Change in Receivables | 1.65 | - | - | - | - | - |
Changes in Inventories | -4.71 | - | - | - | - | - |
Changes in Accounts Payable | 0.9 | - | - | - | - | - |
Changes in Accrued Expenses | -1.02 | - | - | - | - | - |
Changes in Unearned Revenue | 0 | - | - | - | - | - |
Changes in Other Operating Activities | 0.31 | -6.3 | -2.5 | -5.64 | -11.48 | -3.82 |
Operating Cash Flow | 19.42 | 20.01 | 10.68 | 5.91 | -6.08 | -2.09 |
Operating Cash Flow Growth | -4.69% | 87.34% | 80.72% | - | - | - |
Capital Expenditures | -13.72 | -6.36 | -7.47 | -9.88 | -15.47 | -31.07 |
Sale of Property, Plant & Equipment | 0.28 | 0.16 | 2.12 | 0.19 | 0.06 | 0.22 |
Purchases of Investments | -2.77 | - | - | - | - | - |
Other Investing Activities | 0.36 | 0.25 | 0.16 | 0.21 | 0.06 | 0.03 |
Investing Cash Flow | -15.85 | -5.95 | -5.19 | -9.48 | -15.35 | -30.83 |
Short-Term Debt Issued | - | 0.5 | 5.7 | 3 | - | - |
Short-Term Debt Repaid | - | -0 | -2.44 | - | - | - |
Net Short-Term Debt Issued (Repaid) | - | 0.5 | 3.26 | 3 | - | - |
Long-Term Debt Issued | 2 | - | - | - | 61.32 | 10.7 |
Long-Term Debt Repaid | -1.86 | -2.73 | -1.97 | -1.97 | -34 | -0 |
Net Long-Term Debt Issued (Repaid) | 0.14 | -2.73 | -1.97 | -1.97 | 27.32 | 10.7 |
Issuance of Common Stock | 6.3 | - | - | 0.05 | 0.05 | 24.66 |
Repurchase of Common Stock | - | - | -0.28 | -0.37 | - | - |
Net Common Stock Issued (Repurchased) | 6.3 | - | -0.28 | -0.32 | 0.05 | 24.66 |
Other Financing Activities | -2.33 | -4.09 | -4.16 | -4.9 | -1.9 | -2.11 |
Financing Cash Flow | 3.83 | -6.32 | -3.14 | -4.19 | 25.46 | 33.25 |
Effect of Exchange Rate Changes on Cash and Cash Equivalents | - | - | - | -0.08 | -0.08 | 0.06 |
Net Cash Flow | 7.4 | 7.74 | 2.35 | -7.76 | 4.04 | 0.33 |
Free Cash Flow | 5.69 | 13.65 | 3.21 | -3.97 | -21.55 | -33.17 |
Free Cash Flow Growth | -58.30% | 324.86% | - | - | - | - |
FCF Margin | 4.85% | 12.72% | 3.91% | -6.89% | -59.85% | -192.08% |
Free Cash Flow Per Share | 0.06 | 0.15 | 0.04 | -0.04 | -0.25 | -0.43 |
Levered Free Cash Flow | -0.49 | 4.86 | 4.12 | -2.6 | 6.59 | -22.7 |
Unlevered Free Cash Flow | 0.96 | 10.06 | 10.86 | 1.31 | -18.09 | -31.61 |